GlassScriptPhysician profile
Kimberly Ann Saunders
NPI 1174841605
$7,252.25
in general payments reported to CMS, 2019-2025
26 companies · $1,995 in 2025
The $1,995 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.05 · 2023: $2,225 · 2024: $3,020 · 2025: $1,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,090 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,089.92 |
| Education | $150.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,668.42 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $991.42 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $897.97 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $716.30 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $556.34 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $368.52 | 2023-2025 | Airsupra, Farxiga |
| Amgen INC. | $331.10 | 2023-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $305.38 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $254.56 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $227.81 | 2023-2024 | Quviviq |
| Boston Scientific Corporation | $176.72 | 2024-2025 | General - Pain Management |
| Bayer Healthcare Pharmaceuticals INC. | $97.75 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $92.66 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $85.43 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.37 | 2024-2025 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Renalytix Ai, INC. | $80.94 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Dexcom, INC. | $54.06 | 2023-2024 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $42.31 | 2024 | Injectafer |
| Sanofi Pasteur INC. | $40.00 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.21 | 2023-2024 | Trintellix |
| Currax Pharmaceuticals LLC | $33.50 | 2023-2025 | Contrave, Onzetra Xsail |
| Tactile Systems Technology INC | $33.25 | 2024 | Entre Plus, Flexitouch Plus |
| Corium, LLC | $29.91 | 2024 | Azstarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.48 | 2025 | Xifaxan |
| Tolmar, INC. | $15.79 | 2025 | Jatenzo |
| Merck Sharp & Dohme LLC | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Saunders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.